
Merck hires life sciences business head
pharmafile | April 15, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Merck, Merck Millipore, Sigma-Aldrich, udit batra
Merck has confirmed that the current chief executive and president of Merck Millipore Dr Udit Batra has been appointed to lead its combined life science business with Sigma-Aldrich – once the acquisition completes.
Due to finalise mid-2015 they will operate separately, with Batra and Rakesh Sachdev, president and chief executive of Sigma-Aldrich, running both firms.
Batra joined Merck in 2011 from Novartis to head the group’s consumer health business. At Novartis he worked in its vaccines and diagnostics unit where he was head of global public health and market access. He also served in a variety management positions there, including global head of corporate strategy and country president for its pharma business in Australia.
Karl-Ludwig Kley who is the chairman of the executive board at Merck, says: “Udit is a proven leader who has demonstrated his ability to work successfully with his leadership team to guide large organizations, drive performance and deliver to our customers.
“[This] appointment marks another important step in the acquisition of Sigma-Aldrich as it provides stable and strong leadership and continued customer focus during the crucial months of integration planning and beyond.”
Related Content

Merck to acquire Curon Biopharmaceutical’s B-Cell Depletion Therapy
Merck have announced that they have entered into an agreement with private biotechnology company Curon …

Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …

CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma
Merck (known as MSD outside of the US and Canada) has announced that its anti-PD-1 …






